Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internat…
Biotechnology
US, Novato [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q3 | Q1 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | -71.06 | -30.50 | -17.83 | |
| Graham Fair Price | 84.89 | 8.71 | 4.71 | |
| PEG | -96.16 | -0.17 | 4.50 | |
| Price/Book | -64.96 | 28.22 | 80.56 | |
| Price/Cash Flow | -73.50 | -19.41 | 73.25 | |
| Prices/Earnings | -44.94 | -5.80 | -4.00 | |
| Price/Sales | 39.61 | 36.38 | 26.06 | |
| Price/FCF | -73.50 | -19.41 | 73.25 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Weak
Fundamentals
Profitability
| Metric | Q3 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | -14.68 | 0.76 | 0.89 | |
| Operating Margin | -2.67 | -1.52 | -1.48 | |
| ROA | -1.27 | -0.13 | -0.13 | |
| ROE | -5.03 | -1.22 | 75.83 | |
| ROIC | -2.61 | -0.16 | 93.92 | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q3 | Q1 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | 20.59 | -0.53 | 3778.30 | |
| Dividends QOQ | 0.00 | 0.00 | 0.00 | |
| EBIT QOQ | 0.02 | -0.35 | 1735.28 | |
| EPS QOQ | < 0.005 | -0.34 | 3674.67 | |
| FCF QOQ | 1.26 | -1.39 | 9.67 | |
| Revenue QOQ | -0.09 | -0.15 | -53.84 | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Balanced
Fundamentals
Leverage & Liquidity
| Metric | Q3 | Q1 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | 260.51 | 122.51 | -52.97 | |
| Days Sales Outstanding (DSO) | 72.75 | 83.07 | 14.18 | |
| Inventory Turnover | 0.35 | 0.73 | 112.64 | |
| Debt/Capitalization | 0.28 | 0.87 | 214.09 | |
| Quick Ratio | 2.05 | 2.11 | 2.92 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Weak
Fundamentals
Per Share Metrics
| Metric | Q3 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | 0.44 | 1.66 | 276.05 | |
| Cash | 6.17 | 4.96 | -19.53 | |
| Capex | 0.00 | -0.16 | -100.00 | |
| Free Cash Flow | 0.49 | -2.42 | 397.17 | |
| Revenue | 1.37 | 1.29 | -5.63 | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Weak
Fundamentals
Financial Health
06 - Financial Health ·
Bad